Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 19;17(1):80.
doi: 10.1186/s12876-017-0633-6.

Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature

C Venturin  1 , S Nancey  1   2 , P Danion  1 , M Uzzan  3 , M Chauvenet  1 , C Bergoin  1 , X Roblin  4 , B Flourié  1   2 , G Boschetti  5   6   7
Affiliations
Review

Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature

C Venturin et al. BMC Gastroenterol. .

Abstract

Background: Ustekinumab is a fully human monoclonal antibody against the p40 subunit of interleukin (IL) 12 and 23 which is involved in the pathogenesis of several inflammatory diseases. Ustekinumab is approved for psoriasis and psoriatic arthritis treatment and has been successfully evaluated in phase II and III trials for patients with Crohn's disease (CD).

Case presentation: We report here the case of a patient who became pregnant during treatment with ustekinumab for a refractory CD and which ended in miscarriage.

Conclusion: Ustekinumab is a relatively new pharmacotherapy and in addition to this clinical case, we reviewed the published literature concerning the use of this treatment during pregnancy and its consequences on pregnancy and fetus outcome.

Keywords: Anti-IL12/23; Crohn’s disease; Pregnancy; Ustekinumab.

PubMed Disclaimer

References

    1. Khanna R, Preiss JC, MacDonald JK, et al. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2015;5:CD007572. - PubMed
    1. Kopylov G, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease – the McGill experience. J Crohns Colitis. 2014;8:1516–1522. doi: 10.1016/j.crohns.2014.06.005. - DOI - PubMed
    1. Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242–250. doi: 10.1016/j.cgh.2015.09.018. - DOI - PubMed
    1. Khorrami S, Ginard D, Marín-Jiménez I, et al. Ustekinumab for the treatment of refractory Crohn's disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22:1662–1669. doi: 10.1097/MIB.0000000000000842. - DOI - PubMed
    1. Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012;11:1240–1241. - PubMed